• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Medline Inc. announces launch of secondary offering of Class A common stock

    3/3/26 7:02:29 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care
    Get the next $MDLN alert in real time by email

    NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") have commenced an underwritten public offering of 75,000,000 shares of Medline's Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the "SEC"). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline's Class A common stock.

    Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.

    Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets and Carlyle are acting as co-managers for the proposed offering.

    The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected]; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at [email protected]; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at [email protected] and [email protected].

    A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Medline

    Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

      

    Forward-Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "foreseeable," "intend," "may," "plan," "potentially," "predict," "project," "seek," "should," "will," or "would," or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management's current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.

    Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under "Risk Factors" in Medline's registration statement on Form S-1, as amended, relating to the offering and "Item 1A. Risk Factors" in Medline's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline's periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline's filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any "forward-looking statement" made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

    Contacts:

    Investor Relations:

    Karen King

    Global Head Investor Relations

    Patrick Flaherty

    Director, Investor Relations

    (847) 247-7222

    [email protected]

    Media Relations:

    Ben Fox

    Vice President, Corporate Communications

    (224) 327-9999

    [email protected]

    Source: Medline Inc.



    Primary Logo

    Get the next $MDLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDLN

    DatePrice TargetRatingAnalyst
    2/5/2026$55.00Buy
    Tigress Financial
    1/21/2026$50.00 → $55.00Buy
    BTIG Research
    1/12/2026$48.00Buy
    Citigroup
    1/12/2026$38.00Neutral
    BNP Paribas Exane
    1/12/2026$50.00Overweight
    Analyst
    1/12/2026$50.00Overweight
    Piper Sandler
    1/12/2026$48.00Overweight
    Morgan Stanley
    1/12/2026$47.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $MDLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medline Inc. announces launch of secondary offering of Class A common stock

    NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") have commenced an underwritten public offering of 75,000,000 shares of Medline's Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the "SEC"). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline's Class A common stock. Med

    3/3/26 7:02:29 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline Reports Fourth Quarter and Full Year 2025 Results

    Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $180 million, a decrease of 37.7%Fourth quarter Adjusted EBITDA1 of $805 million, approximately flatFull year net sales of $28.4 billion, an increase of 11.5%Full year net income of $1.2 billion, a decrease of 3.6%Full year Adjusted EBITDA1 of $3.5 billion, an increase of 3.2% NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of c

    2/25/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Medline announces participation in the Barclays 28th Annual Global Healthcare Conference

    NORTHFIELD, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, on Wednesday, March 11, 2026, at 9:30am ET. A webcast of the presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for six months following the event. About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all poi

    2/18/26 7:30:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    SEC Filings

    View All

    SEC Form S-1 filed by Medline Inc.

    S-1 - Medline Inc. (0002046386) (Filer)

    3/3/26 6:57:39 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Medline Inc.

    S-8 - Medline Inc. (0002046386) (Filer)

    2/25/26 5:23:28 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Medline Inc.

    10-K - Medline Inc. (0002046386) (Filer)

    2/25/26 4:51:27 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mozart Aggregator Unlv Holdco L.P. claimed ownership of 14,395,879 shares and claimed ownership of 9,501,507 units of Class B Common Stock (SEC Form 3)

    3 - Medline Inc. (0002046386) (Issuer)

    2/23/26 4:30:05 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    New insider Carlyle Mozart Coinvestment Unlv Holdco, L.P. claimed ownership of 15,417,129 shares and claimed ownership of 15,369,974 units of Class B Common Stock (SEC Form 3)

    3 - Medline Inc. (0002046386) (Issuer)

    2/13/26 4:30:19 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Large owner Carlyle Mozart Coinvestment Holdings, L.P. disposed of 15,414,514 shares, decreasing direct ownership by 49% to 16,125,094 units (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    2/13/26 4:30:06 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gic Private Ltd sold $289,480,090 worth of shares (10,204,351 units at $28.37) and bought $364,999,974 worth of shares (12,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 5:26:57 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Andrew J. was granted 30,655 units of Class B Common Stock and bought $74,999,974 worth of shares (2,586,206 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:06 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Director Mills Charles N. was granted 64,005 units of Class B Common Stock and bought $74,799,990 worth of shares (2,579,310 units at $29.00) (SEC Form 4)

    4 - Medline Inc. (0002046386) (Issuer)

    12/22/25 4:30:04 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tigress Financial initiated coverage on Medline with a new price target

    Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00

    2/5/26 10:03:24 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    BTIG Research reiterated coverage on Medline with a new price target

    BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously

    1/21/26 1:17:48 PM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on Medline with a new price target

    Citigroup initiated coverage of Medline with a rating of Buy and set a new price target of $48.00

    1/12/26 10:44:50 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care

    $MDLN
    Financials

    Live finance-specific insights

    View All

    Medline to report fourth quarter and full year 2025 results on February 25, 2026

    NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli

    1/28/26 9:00:00 AM ET
    $MDLN
    Medical/Dental Instruments
    Health Care